ERBB2 and breast carcinoma: Using a panel of five breast cancer cell lines with ErbB2 overexpression, we explicitly demonstrated that HSP90 inhibitor induced the endocytosis and lysosomal degradation of ErbB2, which are accompanied by the ubiquitylation of ErbB2.